AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

Key facts

Sponsor

Changhai Hospital

Principal Investigator

Jin Gang, M.D., MD

Changhai Hospital

Intervention

PDAC(diagnostic_test)

Enrollment

5000 target

Eligibility

18 years · All sexes

Timeline

2024 – 2030

Study locations (3)

• Shanghai Changhai Hospital, Shanghai, Shanghai Municipality, China
• Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China
• Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, Zhejiang, China

Collaborators

Yinzhou Hospital Affiliated to Medical School of Ningbo University · The Second Affiliated Hospital of Jiaxing University · Central Hospital of Lishui City · Jingning County People's Hospital · Alibaba DAMO Academy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Intraductal papillary mucinous carcinoma of pancreas

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07216521
  Intent of Surgery for IPMN
  NYU Langone Health
• RECRUITINGNCT07117045
  Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
  Changhai Hospital
• RECRUITINGNCT06574373
  Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• ACTIVE NOT RECRUITINGNANCT06712797
  Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
  H. Lee Moffitt Cancer Center and Research Institute
• RECRUITINGNCT06694792
  Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
  IRCCS San Raffaele
• ENROLLING BY INVITATIONNCT06276764
  The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
  Adenocyte, LLC
• ACTIVE NOT RECRUITINGPHASE2NCT06519097
  Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
  H. Lee Moffitt Cancer Center and Research Institute
• ENROLLING BY INVITATIONNCT06283576
  Pancreatic Cancer Initial Detection Via Liquid Biopsy
  Karolinska University Hospital

See all trials for Intraductal papillary mucinous carcinoma of pancreas →